kaiser glp-1 coverage 2025 permanente 📌 Starting January 1, 2025, Kaiser Permanente will be making adjustments to the of GLP-1 drugs and other Anti-Obesity Medications (AOMs) in California commercial GLP-1 coverage for obesity treatment

doi:10.1016/j.metabol.2019.04.014 31

The warning does not say tirzepatide causes thyroid cancer in humans

Mark Pimentel, MD, Executive Director of the Medically Associated Science and Technology Program at Cedars-Sinai, and a leading expert on microbial overgrowths, puts it this way: Any factor that slows down the speed of flow [of food] through the small intestine has the potential to cause [bacterial] overgrowth. This is important for patients assessing their SIBO risk, because studies suggest GLP-1 signaling can inhibit aspects of the Migrating Motor Complex (MMC)

Semaglutide is a GLP-1 receptor agonist, meaning it mimics the natural hormone glucagon-like peptide-1 (GLP-1) to regulate appetite and blood sugar levels

Exenatide prolonged the gastric half-emptying time in all diabetic patients without gastroparesis ( n = 20) and worsened the gastric emptying in two of ten diabetics with pre-existing mild gastroparesis [56]